Stepwise Treatment of Hypertension

  • A. Zanchetti
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 93 / 1)


The dilemma whether to treat or not to treat a mild hypertensive patient is thought to be one of the most difficult issues in the management of hypertension. It is intimately connected with the equally important and difficult decisions about adding an antihypertensive drug to the nonpharmacological measures and which substance to use. Indeed, the decision to commence treatment is influenced by the knowledge of the properties and characteristics of the drugs and, on the other hand, by the multiplicity of antihypertensive agents available. These often have different mechanisms of action and pharmacological properties, and the doctor is in the embarrassing position of having to decide which drug should be prescribed first for each individual patient. Are there guidelines that we can offer about choosing the most suitable compound or about combining compounds when necessary?


Calcium Antagonist Antihypertensive Drug Antihypertensive Therapy Mild Hypertension Joint National Committee 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amery A, Birkenhäger WH, Brixho P, Bulpitt C, Clement D,, de Ruyttere M, de Schaepdrijver A et al. (1985) Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1: 1349–1354PubMedCrossRefGoogle Scholar
  2. Amery A, Fagard R, Stassen J (1987) Recent data on changes in lipid metabolism induced by hypotensive drugs. Curr Opin Cardiol 2: 769–774CrossRefGoogle Scholar
  3. Baez MA, Garg DC, Jallard NS, Weidler DJ (1986) Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol. Br J Clin Pharmacol (Suppl 1 ) 21: 63S–68SGoogle Scholar
  4. Boyle RM, Price ML, Hamilton M (1979) Thiazide withdrawal in hypertension. J R Coll Physicians Lond 3: 172–173Google Scholar
  5. Brunner H, Waeber B, Nussberger J (1987) Renal effects of converting enzyme inhibition. J Cardiovasc Pharmacol [Suppl 3] 9: S6–S14CrossRefGoogle Scholar
  6. Bühler FR, Müller FB, Linder L, Bolli P (1985) Antihypertensive therapy and myocardial infarction: focus on calcium antagonists. J Hypertens [Suppl 2] 3: S95–S98CrossRefGoogle Scholar
  7. Chobanian A (1987) Effects of calcium channel antagonists and other antihypertensive drugs on atherogenesis. J Hypertens [Suppl 4] 5: S43–S48CrossRefGoogle Scholar
  8. Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkin CD, Klerman GL, Williams GM (1986) The effect of antihypertensive therapy on quality of life. N Engl J Med 314: 1657–1664PubMedCrossRefGoogle Scholar
  9. Cruickshank JM, Pennert K, Sörman AE, Thorp JM, Zacharias FM, Zacharias FJ (1987) Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other antihypertensives. J Hypertens 5: 489–498PubMedGoogle Scholar
  10. Doyle A (1987) When and how to treat hypertension. In: Hunyor SN (ed) Cardiovascular drug therapy. William and Wilkins, Baltimore, pp 136–141Google Scholar
  11. Dustan HP, Page IH, Tarazi RC, Fröhlich ED (1968) Arterial pressure responses to discontinuing antihypertensive drugs. Circulation 37: 370–379PubMedGoogle Scholar
  12. Erne P, Bolli P, Bertel O, Hulten L, Kiowski W, Müller FB, Bühler F (1983) Factors influencing the hypotensive effects of calcium antagonists. Hypertension 5: 96–102Google Scholar
  13. Finnerty FA (1984) Step-down treatment of mild systemic hypertension. Am J Cardiol 53: 1304–1307PubMedCrossRefGoogle Scholar
  14. Fletcher AE, Franks PJ, Bulpitt CJ (1988) The effect of withdrawing antihypertensive therapy: a review. J Hypertens 6: 431–436PubMedCrossRefGoogle Scholar
  15. Fozzard JR, Mir AK (1987) Are 5HT receptors involved in the antihypertensive effects of Urapidil (Abstr)? Br J Clin Pharmacol 90: 24Google Scholar
  16. Freis ED (1987) Can drug treatment be stopped? In: Strasser T, Ganten D (eds) Mild hypertension: from drug trials to practice. Raven, New York, pp 251–256Google Scholar
  17. IPPPSH Collaborative Group (1985) Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker Oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 3: 379–392CrossRefGoogle Scholar
  18. Jenkins AC, Dreslinski GR, Tadros SS, Groel JT, Fand R, Herczeg SA (1985) Captopril in hypertension: seven years later. J Cardiovasc Pharmacol [Suppl 1] 7: S96–S101CrossRefGoogle Scholar
  19. Langford HG, Blaufox MD, Oberman A, Hawkins CM, Curb JD, Cutter GR, Wassertheil-Smoller S, et al. (1985) Dietary therapy slows the return of hypertension after stopping prolonged medication. JAMA 253: 657–664PubMedCrossRefGoogle Scholar
  20. Leonetti G, Sala C, Bianchini C, Terzoli L, Zanchetti A (1980) Antihypertensive and renal effects of orally administered verapamil. Eur J Clin Pharmacol 18: 375–382PubMedCrossRefGoogle Scholar
  21. Leren P (1987) Comparison of effects on lipid metabolism of antihypertensive drugs with alpha-and beta-adrenergic antagonist properties. Am J Med [Suppl 1A] 82: 31–35CrossRefGoogle Scholar
  22. Levinson PD, Khatri IM, Freis ED (1982) Persistence of normal BP after withdrawal of drug treatment in mild hypertension. Arch Intern Med 142: 2265–2268PubMedCrossRefGoogle Scholar
  23. Lichter I, Richardson PJ, Wyke MA (1986) Differential effects of atenolol and enalapril on memory during treatment for essential hypertension. Br J Clin Pharmacol 21: 641–646PubMedGoogle Scholar
  24. Maland LJ, Lutz LJ, Castle CH (1983) Effects of withdrawing diuretic therapy on blood pressure in mild hypertension. Hypertension 5: 539–544PubMedGoogle Scholar
  25. Management Committee (1982) The Australian Therapeutic Trial in Mild Hypertension: untreated mild hypertension. Lancet 1: 185–191Google Scholar
  26. Mancia G, Bertinieri G, Grassi G, Parati G, Pomidossi G, Ferrari A, Gregorini L, Zanchetti A (1983) Effects of blood pressure measurement by the doctor on patient’s blood pressure and heart rate. Lancet 2: 695–698PubMedCrossRefGoogle Scholar
  27. Mancia G, Parati G, Pomidossi G, Grassi G, Casadei R, Zanchetti A (1987) Alerting reaction and rise in blood pressure during measurement by physician and nursse. Hypertension 9: 209–215PubMedGoogle Scholar
  28. McFate Smith W, Kulaga SF, Moncloa F, Pingeon R, Walker JF (1984) Overall tolerance and safety of enalapril. J Hypertens [Suppl 2] 2: 113–117Google Scholar
  29. Medical Research Council Working Party (1985) MRC trial of treatment of mild hypertension: principal results. Br Med J 291: 97–104CrossRefGoogle Scholar
  30. Medical Research Council Working Party (1988) Stroke and coronary heart disease in mild hypertension: risk factors and the value and treatment. Br Med J 296: 1565–1570CrossRefGoogle Scholar
  31. Nayler WG, Panagiotopoulos S, Elz JS, Sturrock WJ (1987) Fundamental mechanisms of action of calcium antagonists in myocardial ischemia. Am J Cardiol 59: 75B–83BPubMedCrossRefGoogle Scholar
  32. Page IH, Dustan HP (1962) Persistence of normal blood pressure after discontinuing treatment in hypertensive patients. Circulation 25: 433–436Google Scholar
  33. Perry HM, Schroeder HA, Catanzaro FJ, Moore–Jones D, Camel GH (1966) Studies on the control of hypertension. VI. Mortality, morbidity, and remissions during twelve years of intensive therapy. Circulation 33: 958–972Google Scholar
  34. Stamler R, Stamler J, Grimm R, Gösch FC, Elmer P, Dyer A, Berman R, et al. (1987) Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial—the Hypertension Control Program. JAMA 257: 1484–1491Google Scholar
  35. Thurm RH, Smith WM (1967) On resetting of “barostats” in hypertenssive patients. JAMA 201: 301–304CrossRefGoogle Scholar
  36. Trost BN, Weidmann P (1987) Effects of calcium antagonists on glucose homeostasis and serum lipid in non–diabetic and diabetic subjects: a review. J Hypertens [Suppl 4] 5: S81–S104CrossRefGoogle Scholar
  37. US Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (1977) A comparative study. JAMA 237: 255–261CrossRefGoogle Scholar
  38. US Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (1984) The 1984 report. Arch Intern Med 144: 1045–1057CrossRefGoogle Scholar
  39. US Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (1988) The 1988 report. Arch Intern Med 148: 1023–1038CrossRefGoogle Scholar
  40. Varihoutte P, Amery A, Birkenhäger W, Breckenridge A, Bühler F, Distler A, Dormandy J, et al. (1988) Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension 1: 111–133Google Scholar
  41. Veterans Administration Cooperative Group on Antihypertensive Agents (1975) Return of elevated blood pressure after withdrawal of antihypertensive drugs. Circulation 51: 1107–1113Google Scholar
  42. Weinstein DB, Heider JG (1987) Antiatherogenic properties of calcium antagonists. Am J Cardiol 59: 163B–172BPubMedCrossRefGoogle Scholar
  43. WHO/ISH (1983) Guidelines for the treatment of mild hypertension. Bull WHO 61: 53–56Google Scholar
  44. Wikstrand J, Warnold I, Olsson G, Tuomilethto J, Elmfeldt D, Berglund G (1988) Primary Prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 259: 1976–1982Google Scholar
  45. Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, Hörmkvist P-E, et al. (1987) Beta–blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 5: 561–572PubMedCrossRefGoogle Scholar
  46. Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta-blockade during and after myocardial infarction: an overview of randomized trials. Prog Cardiovasc Dis 27: 353–371CrossRefGoogle Scholar
  47. Zachariah PK (1987) Quality of life with antihypertensive medication. J Hypertens [Suppl 4] 5: S105–S110CrossRefGoogle Scholar
  48. Zanchetti A (1980) Rational approaches to clinical therapy. In: Turner P (ed) Clinical pharmacology and therapeutics. MacMillan, London, pp 270–274Google Scholar
  49. Zanchetti A (1985a) A re-examination of stepped–care: a retrospective and prospective. J Cardiovasc Pharmacol [Suppl 1] 7: S126–S131CrossRefGoogle Scholar
  50. Zanchetti A (1985b) Which drug to which patient? J Hypertens [Suppl 2] 3: S57–S63Google Scholar
  51. Zanchetti A (1987a) Step–wise treatment: Which step first? In: Strasser T, Ganten D (eds) Mild hypertension: from drug trials to practice. Raven, New York, pp 243–249Google Scholar
  52. Zanchetti A (1987b) Current drug treatment of hypertension: problems and perspectives. Ann Life Ins Med 81: 149–155Google Scholar
  53. Zanchetti A (1987c) Role of calcium antagonists in systemic hypertension. Am J Cardiol 59: 130B–136BPubMedCrossRefGoogle Scholar
  54. Zanchetti A (1988) What blood pressure level should be treated? In: Laragh JH, Brenner BM (eds) Hypertension: pathophysiology, diagnosis, and management. Raven, New York (in press)Google Scholar
  55. Zanchetti A, Leonetti G (1985) Natriuretic effect of calcium antagonists. J Cardiovasc Pharmacol [Suppl 4] 7: S33–S37CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • A. Zanchetti

There are no affiliations available

Personalised recommendations